The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Updates on DREAMM-6 and DREAMM-2 in R/R myeloma
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, of the University College London Hospitals, London, UK, discusses the safety and tolerability of belantamab mafodotin, a BCMA targeting antibody-drug conjugate, in combination with bortezomib/dexamethasone in relapsed/refractory (R/R) multiple myeloma patients as evaluated in the DREAMM-6 study (NCT03544281) as well against selinexor and dexamethasone as evaluated in the DREAMM-2 study (NCT03525678). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
